Daily Ards Research Analysis
Three ARDS-focused studies stand out today: a pooled population PK analysis shows IL-6R inhibitors increase unbound imatinib despite elevated AAG in COVID-19 ARDS; a chest X-ray-based UTAMI score approaches Berlin Definition accuracy to predict ICU need in pneumonia-related ARDS; and a mechanistic mouse study reveals interferon-gamma exerts opposite effects on kidney injury and MA-ARDS depending on malaria strain.
Summary
Three ARDS-focused studies stand out today: a pooled population PK analysis shows IL-6R inhibitors increase unbound imatinib despite elevated AAG in COVID-19 ARDS; a chest X-ray-based UTAMI score approaches Berlin Definition accuracy to predict ICU need in pneumonia-related ARDS; and a mechanistic mouse study reveals interferon-gamma exerts opposite effects on kidney injury and MA-ARDS depending on malaria strain.
Research Themes
- Critical-illness pharmacokinetics and protein binding
- Imaging-based ARDS risk stratification
- Cytokine-mediated organ injury in infectious ARDS
Selected Articles
1. The differential effect of Interferon-gamma on acute kidney injury and parasitemia in experimental malaria.
In two murine malaria models, IFN-gamma deficiency had opposing effects: it protected PbNK65-infected mice from MAKI and MA-ARDS with lower parasitemia and injury markers, but worsened PcAS-induced kidney injury with higher parasitemia. IFN-gamma consistently induced renal CXCL10 without altering TNF-alpha, underscoring a strain-dependent, cytokine-mediated pathophysiology.
Impact: This work reveals a context-dependent role of IFN-gamma in malaria-associated organ injury, including MA-ARDS, cautioning against uniform cytokine targeting and informing host-directed therapies.
Clinical Implications: Cytokine-modulating therapies in infectious ARDS should account for pathogen- and context-specific effects; IFN-gamma blockade may benefit some malaria phenotypes but harm others.
Key Findings
- IFN-gamma deficiency protected PbNK65-infected mice from MAKI and MA-ARDS, with low parasitemia, minimal renal histopathology, and reduced NGAL.
- In PcAS infection, IFN-gamma deficiency increased parasitemia and aggravated kidney injury, with proteinuria, hyaline casts, and elevated renal HO-1 and NGAL mRNA.
- IFN-gamma induced renal CXCL10 in both models without affecting TNF-alpha expression.
Methodological Strengths
- Comparative design across two malaria models clarifies strain-dependent effects.
- Multiple orthogonal readouts (parasitemia, histology, NGAL/HO-1, cytokines) enhance mechanistic inference.
Limitations
- Mouse models may not fully recapitulate human malaria pathophysiology.
- Cellular sources/targets of IFN-gamma and CXCL10 were not delineated.
Future Directions: Validate findings in human malaria cohorts with ARDS/AKI phenotyping; dissect cellular pathways of IFN-gamma/CXCL10; test host-directed interventions stratified by parasite species.
Malaria-associated acute kidney injury (MAKI) is a common complication of Plasmodium infection, affecting ~ 50% of severe malaria cases and associated with increased mortality. However, its immunopathogenesis remains unclear. Interferon-gamma (IFN-gamma) is a crucial cytokine that influences parasite clearance and mediates pathogenesis in experimental models of malaria. This study explored the role of IFN-gamma in kidney pathology in C57BL/6 mice infected with Plasmodium berghei NK65 (PbNK65) and P. chabaudi AS (PcAS). PbNK65-infected mice, normally susceptible to severe malaria, were protected from both MAKI and malaria-associated acute respiratory distress syndrome (MA-ARDS) when lacking IFN-gamma. Infected IFN-gamma knockout (KO) mice developed low parasitemia levels, minimal kidney histopathological changes and reduced expression of the kidney injury marker Neutrophil Gelatinase-Associated Lipocalin (NGAL). In contrast, upon PcAS-infection, IFN-gamma deficiency led to increased parasitemia and aggravated kidney pathology, evidenced by proteinuria, hyaline casts in kidneys and increased renal mRNA expression of Heme Oxygenase 1 (HO-1) and NGAL. In both models, IFN-gamma induced renal C-X-C Motif Chemokine Ligand 10 (CXCL10) but did not affect Tumor Necrosis Factor-alpha (TNF-alpha) expression. Our data indicate that IFN-gamma exerts a dual effect on kidney pathology, which is conditioned by the mouse model and its impact on parasitemia.
2. Disease-Drug-Drug Interaction of Imatinib in COVID-19 ARDS: A Pooled Population Pharmacokinetic Analysis.
Pooled population PK across COVID-19 and oncology cohorts shows that IL-6R inhibitors increase imatinib’s unbound fraction in ICU COVID-19 patients despite higher AAG, indicating altered metabolism and protein binding. Reliance on total concentrations may misestimate target-site exposure for imatinib and other highly protein-bound drugs.
Impact: Demonstrates a clinically relevant disease–drug–drug interaction affecting unbound exposure in critical illness, challenging standard therapeutic monitoring based on total concentrations.
Clinical Implications: Consider unbound (free) drug monitoring or adjusted interpretation of total levels when IL-6R inhibitors are co-administered in COVID-19 ARDS; extrapolate caution to other highly protein-bound agents in ICU.
Key Findings
- In ICU COVID-19 patients receiving IL-6R inhibitors, imatinib unbound fraction was significantly higher than in CML/GIST patients (4.66% vs 3.54% [1.08%–8.51%]; p<0.001).
- Despite approximately twofold higher AAG levels, co-treatment with IL-6R inhibitors altered imatinib metabolism and protein binding.
- Total plasma concentrations may not reflect unbound target-site concentrations for imatinib and similar highly protein-bound drugs.
Methodological Strengths
- Pooled population PK modeling integrating COVID-19 and CML/GIST datasets.
- Direct quantification of total and unbound imatinib and its metabolite with AAG measurement.
Limitations
- Observational design with heterogeneous cohorts; causality cannot be established.
- Clinical outcome impact and dosing adjustments were not evaluated prospectively.
Future Directions: Prospective studies incorporating unbound therapeutic drug monitoring and evaluating clinical outcomes; assess generalizability to other highly protein-bound ICU drugs.
Prior pharmacokinetic (PK) analysis revealed that increased alpha-1-acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID-19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N-desmethyl imatinib in hospitalized patients with different severities of COVID-19, and to assess the impact of critical illness and the potential drug-drug interaction with IL-6R inhibitors on imatinib exposure. Imatinib, N-desmethyl imatinib, and AAG were quantified from collected plasma samples. The PK data was further combined with previous data from COVID-19 patients and chronic myelogenous leukemia/gastrointestinal stromal tumor (CML/GIST) patients who received imatinib. A population PK analysis was conducted using a standard sequential approach. Unbound fraction in COVID-19 patients admitted to the intensive care unit (ICU) and treated with IL-6R inhibitors was significantly elevated compared to CML/GIST patients (4.66% vs. 3.54% [1.08%-8.51%]; p < 0.001), despite twofold increased AAG levels. Our findings on total and unbound concentration show that cotreatment with IL-6R inhibitor can lead to changes in metabolism and protein binding, suggesting similar implications for other highly protein bound drugs. Consequently, total concentrations may not accurately reflect unbound target site concentrations.
3. The UTAMI score: a chest x-ray-based tool for predicting ICU admission in ARDS of pneumonia patients.
In 318 pneumonia admissions, the chest X-ray-based UTAMI method achieved AUROC 79.6% for identifying ARDS requiring ICU care, approaching the Berlin Definition’s 81.2% that uses clinical and laboratory data. Key predictors for ICU need via UTAMI were CAD history, CRP, and oxygen saturation, enabling simplified early triage.
Impact: Offers a rapid, resource-light ARDS triage tool with near-gold-standard discrimination, potentially valuable in emergency and resource-limited settings.
Clinical Implications: Clinicians can leverage chest radiographs plus minimal clinical data (CAD history, CRP, SpO2) to flag high-risk ARDS cases for ICU, expediting care in busy or resource-limited environments.
Key Findings
- UTAMI, based on chest radiographs, achieved AUROC 79.6% for predicting ARDS requiring ICU admission, close to the Berlin Definition’s 81.2%.
- CRP was a consistent predictor (PR 1.28 in Berlin-aligned predictors; PR 1.71 in UTAMI) alongside oxygen saturation and CAD history for ICU risk.
- Neutrophils, CRP, D-dimer, oxygen saturation, and respiratory rate predicted ARDS by Berlin Definition; moderate-severe ARDS cases were admitted to ICU.
Methodological Strengths
- Direct head-to-head comparison against Berlin Definition with AUROC analysis.
- Relatively large single-center cohort (n=318) with clinical and laboratory covariates assessed.
Limitations
- Single-center, cross-sectional design without external validation.
- Potential confounding and misclassification; reliance on chest X-ray quality and interpretation.
Future Directions: External validation in multicenter cohorts; prospective impact studies on triage and outcomes; integration with AI-assisted radiograph analysis.
PURPOSE: This study proposes and evaluates the Universal Thorax ARDS Modification Index (UTAMI), a new method based on chest x-ray findings, for rapid ICU admission prediction in pneumonia with ARDS. Clinical and laboratory variables are analyzed to find potential predictors. METHOD: A cross-sectional study at Fatmawati Central General Hospital (2022-2023) compared the diagnostic accuracy of UTAMI method against the gold standard for ARDS diagnosis; Berlin Definition. We analyzed 318 patients' data that were hospitalized for pneumonia. Clinical and laboratory predictors of ARDS were also analyzed. RESULTS: Neutrophil levels, CRP, D-dimer, oxygen saturation, and respiratory rate can predict ARDS diagnosis according to the Berlin Definition. The patient cohort showed that those with moderate-severe ARDS were admitted to the ICU. With ARDS categorized as ARDS requiring ICU admission (ARDS ICU) and ARDS not requiring ICU admission, the UTAMI method requires only history of coronary artery disease (CAD), CRP, and oxygen saturation as key predictors. CRP was a predictor in both the Berlin Definition (PR 1.28) and the UTAMI method (PR 1.71). In the AUROC test, the Berlin Definition distinguished moderate-severe ARDS with 81.2% accuracy using chest radiographs, clinical and laboratory values. The UTAMI method, based solely on chest radiographs achieved 79.6% accuracy, showing fair discrimination against the gold standard. CONCLUSION: UTAMI Score is a viable tool for predicting the risk of ARDS in pneumonia. Utilizing UTAMI method, ARDS can be predicted using only chest radiograph, making it easier for clinicians to be alerted earlier. Predicting ARDS ICU from UTAMI method requires only 3 variables; CAD comorbid, laboratory CRP and peripheral oxygen saturation.